What is claimed is:

1. A combination comprising a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, with one or more therapeutic agents selected from the group consisting of abacavir, efavirenz, and lopinavir.

2. A combination according to claim 1 wherein the therapeutic agent is abacavir.

3. A combination according to claim 1 or 2 wherein the pharmaceutically acceptable salt of a compound of formula (I) is the sodium salt.

4. A combination according to claim 2 additionally containing lamivudine.

5. Use of a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, with one or more therapeutic agents selected from the group consisting of abacavir, efavirenz, and lopinavir, in the manufacture of a medicament for treatment of HIV infection.

6. The use according to claim 5 wherein the therapeutic agent is abacavir.

7. The use according to claim 5 or 6 wherein the pharmaceutically acceptable salt of a compound of formula (I) is the sodium salt.

8. The use according to claim 6 additionally containing lamivudine.

9. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or 2 and one or more therapeutic agents selected from the group consisting of abacavir, efavirenz, and lopinavir together with a pharmaceutically acceptable carrier therefor.

10. A pharmaceutical composition according to claim 9 wherein the therapeutic agent is abacavir.

11. A pharmaceutical composition according to claim 7 or 8 wherein the pharmaceutically acceptable salt of a compound of formula (I) is the sodium salt.

12. A pharmaceutical composition according to claim 10 additionally containing lamivudine.

13. A combination according to any of claims 1 - 4 wherein the combination is administered simultaneously.

14. A combination according to any of claims 1 – 4 wherein the combination is administered sequentially.

15. The use according to any of claims 5 - 8 wherein the compound of formula (I) and the therapeutic agent(s) are to be administered simultaneously.

16. The use according to any of claims 5 – 8 wherein the compound of formula (I) and the therapeutic agent(s) are to be administered sequentially.

17. A patient pack comprising a compound of formula (I) according to claim 1 and one or more therapeutic agents selected from the group consisting of abacavir, efavirenz, and lopinavir.

CLAIMS

1. A combination comprising a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof, and lamivudine.

2. A combination according to claim 1 wherein the pharmaceutically acceptable salt of a compound of formula (I) is the sodium salt.

3. A combination according to claim 1 or 2 wherein the pharmaceutically acceptable salt of abacavir is the hemisulfate salt.

4. A combination according to any of claims 1 - 3 for use in medical therapy.

5. A combination according to any of claims 1 - 3 for use in the treatment of HIV infection.

6. A pharmaceutical composition comprising a combination according to any of claims 1 – 3 together with a pharmaceutically acceptable carrier therefor.

7. A combination according to any of claims 1 - 3 wherein the combination is administered simultaneously.

8. A combination according to any of claims 1 – 3 wherein the combination is administered sequentially.

9. Use of a combination according to any of claims 1 - 3 for the manufacture of a medicament for the treatment of HIV infection.